RAB39B：一种通过多组学和功能验证确定的急性髓系白血病新型生物标志物。
RAB39B: A novel biomarker for acute myeloid leukemia identified via multi-omics and functional validation.
作者信息
Chen Shuo, Li Mengxing, Wang Jishi
机构信息
Department of Hematology, Affiliated Medicine of Guizhou Medical University, Guiyang, 550001, China.
Graduate School, Guizhou Medical University, Guiyang, 550001, China.
出版信息
Open Med (Wars). 2025 Mar 28;20(1):20251168. doi: 10.1515/med-2025-1168. eCollection 2025.
BACKGROUND
The objective of this research was to investigate the involvement of RAB39B in acute myeloid leukemia (AML) using bioinformatics analysis and experiments for validation.
METHODS
In this article, RNA sequencing data from The Cancer Genome Atlas and genotype-tissue expression were utilized to analyze the expression of RAB39BA and identify differentially expressed genes.
RESULTS
AML exhibited elevated expression of RAB39B in diverse tumor types. In laboratory experiments, it has been demonstrated that RAB39B exhibits a significant expression level in AML cell lines when compared to normal peripheral blood monocytes. Moreover, RAB39B is closely linked to the growth and programmed cell death of AML cells.
CONCLUSION
In conclusion, RAB39B shows potential as a biomarker for the identification and prediction of AML, contributing to the growth and cell death processes in AML.
背景
本研究的目的是通过生物信息学分析和实验验证来研究RAB39B在急性髓系白血病（AML）中的作用。
方法
在本文中，利用来自癌症基因组图谱的RNA测序数据和基因型-组织表达来分析RAB39BA的表达并鉴定差异表达基因。
结果
AML在多种肿瘤类型中表现出RAB39B表达升高。在实验室实验中，已证明与正常外周血单核细胞相比，RAB39B在AML细胞系中表现出显著的表达水平。此外，RAB39B与AML细胞的生长和程序性细胞死亡密切相关。
结论
总之，RAB39B显示出作为AML识别和预测生物标志物的潜力，有助于AML的生长和细胞死亡过程。
Zotero 插件